drugset / Trial / NCT01835665
Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
Phase 1
Completed
8 enrolled
University of California, San Francisco
The Bluefield Project to Cure Frontotemporal Dementia · collab
NaSingle-groupOpen-label
Summary
The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as the safety and tolerability of oral nimodipine in progranulin mutation carriers in preparation for longer term efficacy studies in patients with frontotemporal dementia due to progranulin gene mutations.
Timeline
- Start
- 2013-03
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimodipine | Small molecule | — | Oral |